Johnson & Johnson: Innovative Medicine Growth Offsets Stelara Decline
Johnson & Johnson (NYSE: JNJ) reported strong performance in its innovative medicines segment, which helped offset the decline from its top-selling drug, Stelara. The company's Non-GAAP earnings per share of $2.59 beat expectations by $0.06 while revenue came in at $25.4 billion as anticipated. Long-term data for J&J’s Tremfya showed sustained remission rates for Crohn’s disease patients over three years, reinforcing its value proposition and potential to replace Stelara's waning sales due to patent expiration. Analysts are watching how well the company can transition into this new phase with a focus on innovative therapies. The results highlight J&J's ability to maintain revenue stability despite challenges in key therapeutic areas.